TY - JOUR
T1 - Sudden cardiac death after acute heart failure hospital admission
T2 - Insights from ASCEND-HF
AU - Pokorney, Sean D.
AU - Al-Khatib, Sana M.
AU - Sun, Jie-Lena
AU - Schulte, Phillip
AU - O'Connor, Christopher M.
AU - Teerlink, John R.
AU - Armstrong, Paul W.
AU - Ezekowitz, Justin A.
AU - Starling, Randall C.
AU - Voors, Adriaan A.
AU - Velazquez, Eric J.
AU - Hernandez, Adrian F.
AU - Mentz, Robert J.
PY - 2018/3
Y1 - 2018/3
N2 - Aims The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined.Methods and results We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n= 121). Ten patients had more than one event with 30-day Kaplan-Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%-0.9%, n= 43], 0.4% for RSCD (95% CI 0.2%-0.5%, n= 24), and 0.9% for VT/VF (95% CI 0.7%-1.2%, n= 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8-9.1, P <0.0001).Conclusions Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
AB - Aims The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined.Methods and results We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n= 121). Ten patients had more than one event with 30-day Kaplan-Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%-0.9%, n= 43], 0.4% for RSCD (95% CI 0.2%-0.5%, n= 24), and 0.9% for VT/VF (95% CI 0.7%-1.2%, n= 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8-9.1, P <0.0001).Conclusions Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
KW - Heart failure
KW - Implantable cardioverter-defibrillator
KW - Sudden cardiac death
KW - Ventricular tachycardia
KW - Ventricular fibrillation
KW - PRESERVED EJECTION FRACTION
KW - MYOCARDIAL-INFARCTION
KW - RISK
KW - PREDICTORS
KW - TRIAL
KW - DEFIBRILLATOR
KW - NESIRITIDE
KW - PROGRAM
KW - SOCIETY
KW - DISEASE
U2 - 10.1002/ejhf.1078
DO - 10.1002/ejhf.1078
M3 - Article
SN - 1388-9842
VL - 20
SP - 525
EP - 532
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 3
ER -